Arcturus (ARCT) Q2 2026 Earnings Call Transcript
Arcturus Therapeutics (ARCT) reported Q2 2026 revenue of $3M ($5M for six months) versus $28.3M and $57.7M a year earlier, citing lower recognition tied to the CSL Seqirus collaboration termination process. Net loss was $23.8M ($0.84/share). Cash was $191.5M, with a runway through 2028. Company regained global rights to KOSTAIVE and received a $12M one-time payment. Phase II ARCT-032 enrollment continues, with a Phase III decision expected in Q4 2026.
How this was made
The 30-second read
Why it matters
Key trading inputs are the disclosed settlement cash ($12M), regained global rights to KOSTAIVE and vaccine platform, and management’s stated decision timing for advancing ARCT-032 into Phase III in Q4 2026, plus an expected Q3 2026 OTC data and regulatory plan update.
Market read
This is a pipeline-and-contract execution update with explicit cash runway and multiple dated clinical/regulatory milestones that can drive sentiment into Q3 2026 and Q4 2026.
What to watch
Revenue collapse is tied to recognition timing under CSL termination, so investors may over-interpret the revenue decline as demand weakness rather than accounting/contract-structure effects.
Background
Arcturus’ Q2 2026 call centers on the end of its sa-mRNA collaboration with CSL Seqirus, alongside updates across cystic fibrosis (ARCT-032) and OTC deficiency (ARCT-810) programs.
Ticker impact
Arcturus reported Q2 2026 results and said it regained global rights to KOSTAIVE plus a $12M one-time cash payment after CSL termination.
Moderate upside bias on renewed confidence in asset control and clearer regulatory/clinical path, offset by sharply lower recognized revenue and ongoing cash burn.
The call discloses multiple decision-relevant items: cash runway through 2028, a specific $12M settlement payment, regained global rights, and a stated Q4 2026 Phase III advancement decision timeline for ARCT-032.
Market effects
Highlights how sa-mRNA platform companies can re-center strategy after partner terminations, with manufacturing and regulatory execution becoming key differentiators.
Japan partnership shift for KOSTAIVE profit share may influence regional commercialization expectations for respiratory vaccines.
US FDA Type C follow-up and planned OTC regulatory plan update can affect perceived execution credibility across rare-disease mRNA peers.
Counterpoint
The headline improvement in rights may not translate into near-term value if clinical timelines slip or if manufacturing exclusivity economics with Thermo Fisher prove costly.
Key entities
- companyArcturus Therapeutics
US-listed biotech whose Q2 2026 earnings call disclosed CSL settlement terms, cash runway, and clinical/regulatory timelines.
- counterpartyCSL Seqirus
Partner whose collaboration termination triggered regained rights and a one-time $12M cash payment to Arcturus.
- partnerThermo Fisher
Will provide manufacturing support and exclusive commercial manufacturing rights for ARCT-032 subject to regulatory approval.
- partnerMeiji Seika Pharma
Japan commercialization partner for KOSTAIVE, with a shift from three-way to two-way profit share.
- regulatorFDA
Type C meeting earlier in 2026 informs the supplementary data included in the upcoming Q3 2026 OTC update.
